The 34 references in paper M. Batiushin M., H. Gadaborsheva Z., М. Батюшин М., Х. Гадаборшева З. (2015) “Белок сосудистой адгезии-1 (VAP-1) и его роль в моделировании воспалительного процесса и фиброза. Нефрологический вектор // Vascular adhesive protein-1 (VAP-1) and its role in modeling of inflammation and fibrosis. Nephrology vector” / spz:neicon:nefr:y:2015:i:5:p:23-27

1
Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 1992;
(check this in PDF content)
2
7: 1407–1409 2. Rucker RB, O’Dell BL. Connective tissue amine oxidase I. Purification of bovine aorta amine oxidase and its comparison with plasma amine oxidase. Biochim Biophys Acta Enzymol 1971; 235:32-43
(check this in PDF content)
3
Airenne TT, Nymalm Y, Kidron H et al. Crystal structure of the human vascular adhesion protein-1: Unique structural features with functional implications. Protein Science 2005; 14:1964–1974.
(check this in PDF content)
4
Jalkanen S, Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J. 2001; 20: 3893–3901
(check this in PDF content)
5
Abella A, García-Vicente S, Viguerie N et al. Adipocytes release a soluble form of VAP-1/SSAO by a metalloproteasedependent process and in a regulated manner. Diabetologia 2004; 47: 429–438
(check this in PDF content)
6
Kurkijarvi R, Adams DH, Leino R et al. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 1998; 161: 1549–1557
(check this in PDF content)
7
Salmi M, Jalkanen S. Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans. Blood. 2006; 108: 1555-1561
(check this in PDF content)
8
Tohka S, Laukkanen M-L, Jalkanen S, Salmi M. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates their recruitment in vivo. FASEB J. 2001; 15: 373–382
(check this in PDF content)
9
Salmi M, Yegutkin GG, Lehvonen R et al. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 2001; 14: 265–276
(check this in PDF content)
10
Dunkel P, Balogh B, Meleddu R et al. Semicarbazidesensitive amine oxidase/vascular adhesion protein-1: a patent survey. Expert Opin. Ther. Patents 2011; 21(9): 1453-1471
(check this in PDF content)
11
Kinemuchi H, Sugimoto H, Obata T, Satoh N, Ueda S. Selective inhibitors of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity in mammalian tissues. Neurotoxicology. 2004; 25: 325–335
(check this in PDF content)
12
Merinen M, Irjala H, Salmi M et al. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol. 2005; 166: 793-800
(check this in PDF content)
13
Koskinen K, Vainio PJ, Smith DJ et al. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 2004; 103: 3388-3395
(check this in PDF content)
14
Noonan T, Lukas S, Peet GW et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am. J. Clin. Exp. Immunol. 2013; 2(2): 172-185
(check this in PDF content)
15
Galkina E, Ley K. Vascular Adhesion Molecules in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27: 2292-2301
(check this in PDF content)
16
Jalkanen S, Karikoski M, Mercier N et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood. 2007; 110: 1864 –1870
(check this in PDF content)
17
Morin N, Lizcano JM, Fontana E et al. Semicarbazidesensitive amineoxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes. J Pharmacol Exp Ther 2001; 297: 563-572
(check this in PDF content)
18
Carpene C, Bour S, Visentin V et al. Amine oxidase substrates for impaired glucose tolerance correction. J Physiol Biochem 2005; 61: 405-420
(check this in PDF content)
19
Iffiu-Soltesz Z, Wanecq E, Lomba A et al. Chronic benzylamine administration in the drinking water improves glucose tolerance, reduces body weight gain and circulating cholesterol in high-fat diet-fed mice. Pharmacol Res 2010; 61: 355-363
(check this in PDF content)
20
Mercader J, Iffiu-Soltesz Z, Brenachot X et al. SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders. Future Med Chem 2010; 2: 1735-1749
(check this in PDF content)
21
Noda K, She H, Nakazawa T et al. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J 2008; 22: 2928-2935
(check this in PDF content)
22
Kurkijärvi R, Jalkanen S, Isoniemi H, Salmi M. Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. Eur. J. Immunol. 2001. 31: 2876–2884
(check this in PDF content)
23
Boomsma F, Veldhuisen DJ van, Kam PJ et al. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 1997; 33: 387–391
(check this in PDF content)
24
Airas L, Mikkola J, Vainio JM et al. Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. J of Neuroimmunology 2006; 177: 132–135
(check this in PDF content)
25
Koc-Zorawska E, Malyszko J, Zbroch E et al. Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients. Arch Med Sci 2012; 8(6): 1048-1052
(check this in PDF content)
26
Koc-Zorawska E, Malyszko J, Zbroch E et al. VAP-1 in peritoneally dialyzed patients. Postepy Hig Med Dosw (Online). 2013; 67: 1340-134
(check this in PDF content)
27
Lin M-S, Li H-Y, Wei J-N et al. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clinical Biochemistry 2008; (41): 1362–1367
(check this in PDF content)
28
Lin S., Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular fibroblasts are the primary source of collagenproducing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173: 1617–1627
(check this in PDF content)
29
Kawakami T, Mimura I, Shoji K et al. Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes. Kidney Int Suppl 2014; (4): 107–112
(check this in PDF content)
30
Epstein FH. Oxygen and renal metabolism. Kidney Int 1997; 51: 381–385
(check this in PDF content)
31
Lin SL, Chang FC, Schrimpf C et al. Targeting endotheliumpericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol. 2011; 178: 911–923
(check this in PDF content)
32
Schrimpf C, Teebken OE, Wilhelmi M, Duffield JS. The Role of Pericyte Detachment in Vascular Rarefaction. J Vasc Res 2014; 51: 247–258
(check this in PDF content)
33
Nakao S, Noda K, Zandi S et al. VAP-1–Mediated M2 Macrophage Infiltration Underlies IL-1β – but Not VEGF-A–Induced Lymph- and Angiogenesis. Am J Pathol 2011; 178: 1913–1921
(check this in PDF content)
34
Foot JS, Yow TT, Schilter H et al. PXS-4681A, a Potent and Selective Mechanism-Based Inhibitor of SSAO/VAP-1 with Anti-Inflammatory Effects In Vivo. J Pharmacol Exp Ther 2013; 347: 365–374 Авторы заявляют об отсутствии конфликта
(check this in PDF content)